#Sweden #EQT #Stockholm #Galderma Group AG #stock placement

Introduction

On October 30, 2025, EQT confirmed the successful completion of a significant share placement in Galderma Group AG. This strategic move allows EQT to bolster its financial resources while maximizing the value derived from its equity investments. The transaction marks a pivotal moment for both EQT and Galderma, enhancing their operational capabilities and market presence.

The Share Placement Details

EQT's affiliate associated with EQT VIII conducted an accelerated bookbuilding process, successfully placing 20 million shares in Galderma Group AG (SIX: GALD). This transaction yielded gross proceeds of approximately CHF 2.6 billion, with EQT receiving close to CHF 690 million from this placement.

The placement was carried out with the assistance of notable financial institutions: Citigroup Global Markets, Goldman Sachs International, Jefferies, Merrill Lynch International, Morgan Stanley, and UBS, who served as joint global coordinators and bookrunners. Their participation underscores the importance of this deal in the financial markets.

Significance of the Sale

This successful placement not only strengthens EQT’s financial position but also marks a significant milestone for Galderma Group AG. As a leading global company specializing in dermatology and aesthetic solutions, the influx of capital can help Galderma expand its product lines and innovate in various areas to meet growing consumer demand.

EQT's decision to divest a portion of its stake shows a strategic approach to asset management, where the focus remains on generating returns for its investors while also enabling the company to remain competitive in a dynamic market.

Market Reactions

The sale was well-received in the financial community, signifying strong market interest in Galderma and confidence in its future growth. Investors are optimistic that Galderma will utilize the funds effectively to drive innovation and expand its global footprint, potentially leading to future profitability and shareholder value appreciation.

Regulatory Considerations

It’s important to note that the placement does not constitute an offer to sell or solicit for the buying of Galderma Group AG securities. Moreover, the placement is compliant with Swiss regulations pertaining to financial services. The securities are not offered for sale within the United States due to regulatory stipulations, ensuring that EQT adheres to necessary legal frameworks in their operations.

Looking Forward

As EQT continues its journey in the private equity landscape, this transaction exemplifies a deliberate and calculated strategy to optimize their portfolio performance. EQT's leadership is focused on identifying high-growth opportunities and maximizing asset value, paving the way for future investments.

In conclusion, the completion of this sale represents not just a transaction but a strategic realignment for EQT and a promising avenue for Galderma, with expectations for growth and innovation on an international scale. As both entities move forward, stakeholders will be keenly watching how these new funds will be utilized to foster development and enhance market positioning.